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Summary
In this study we evaluated 38 TM patients (recruited from the
Thalassemia centre of Palermo), 14 male and 24 female. We
obtained the BMD of the lumbar spine (L1 L4), femoral neck
(DEXA; Lunar DPX plus), serum levels of PTH, osteocalcin, C-
telopeptide and bone alkaline phosphatase.
Patients with TM presented low bone mass at lumbar spine (Z
score: L1-L4 -2.23 ± 1.25 SD), and femoral neck (Z-score -1.52 ±
1.14 SD): 50% of subjects were osteoporotic; 36% osteopenics
and 13.1% were normal. Were presented normal serum levels of
osteocalcin (19.1 ± 8 ng/ml), but hight level of bone alkaline phos-
phatase (24.2 ± 9.1 g/L), and C-telopeptide (4528 ± 2821 pmol/L).
Patients with TM presented BMD reduction more marked at
lumbar spine than femur; increased C telopeptides and alka-
line phosphatase were observed, although osteocalcin was
normal. Patients with TM presented low bone mineral density
and high bone turnover. It’s possible that subjects with in-
creased reabsorbtion, have a marked bone loss and a pro-
gressive increased fracture risk. 
KEY WORDS: thalassemia major, bone mineral density, bone turnover, os -
teoporosis.
Introduction
Beta Thalassemia Major (TM) affects a significant number of
the population in certain areas of the world (1).
TM is an inherited blood disorder in which the body is unable to
make adequate hemoglobin. This is due to an inborn error of
metabolism that leads to absence or reduced synthesis of one
or more types of globin polypeptide chains of the hemoglobin
molecule; is a hereditary disorder of haemoglobin synthesis re-
sulting in severe anemia. Treatment consists of multiple blood
transfusions, a complication of which is iron overload. Exces-
sive iron is then deposited in almost all tissues but primarily in
the liver, heart and the endocrine glands (2).
The bone marrow expands to compensate for anemia and as a
result there occur marked skeletal changes leading to frontal
and parietal bossing, malar prominence, protrusion of upper
jaw leading to malocclusion of teeth, distortion of ribs, verte-
brae and weakening of long bones, low bone mass.
Patients and methods
38 TM patients (recruited from the thalassemia centre of Paler-
mo) were studied (14 male and 24 female), age range 20-40
years old. Osteoporosis was defined using the standard World
Health Organization criteria (z-score of BMD lower than 2·5).
The BMD of the lumbar spine (L1-L4), the femoral neck and
the forearm was determined by Dual Energy X-Ray Absorp-
tiometry (DEXA; Lunar DPX plus).The PTH was studied by
ELISA (Biosource, Belgium), osteocalcin, C-telopeptide and
bone alkaline phosphatase by Elisa (Beckmann-Coulter USA).
Analisys of variance and U test of Mann-Whitney were used for
TM patients and controls. The correlation was obtained with
Pearson index. P value < 0.05 was considered statistically sig-
nificant. The calculated z-scores for males and females were
evaluated by normal ranges.
Results 
Patients with TM presented low bone mass at lumbar spine (Z
score: L1-L4 -2.23 ± 1.25 SD) (Fig. 1), and femoral neck (Z-
score -1.52 ± 1.14 SD) (Fig. 2): 50% of subjects were osteo-
porotic; 36% osteopenics and 13.1% were normal (Fig. 3).
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F i g u r e1 - Z-score lumbar spine. Low bone mass at lumbar spine inT M
women and men (Z-score: L1-L4 -2.23 ± 1.25).
F i g u r e2 - Z-score femoral neck. T-score femoral neck: patients with TM
presented low bone mass at femoral neck (Z-score -1.52 ± 1.14).
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F i g u r e 3 - Prevalence of osteopenia and osteoporosis inTM patients.
Prevalence of osteoporosis and osteopenia inTM patients: 50% of sub-
jects were osteoporotic; 36% osteopenic and 13.1% were normal.
F i g u r e4 - Serum levels of osteocalcin. Normal serum levels of osteocalcin
i nTM (19.1 ± 8 ng/ml).
F i g u r e5 - Serum levels of bone alkaline phosphatase. High serum levels
of bone alkaline phosphatase in TM (24.2 ± 9.1 mg / L ) .
F i g u r e6 - Serum level of C-telopeptide. High serum levels of C-telopep-
tide inTM (4528 ± 2821 pmol/L).
Compared to normal subjects, thalassemic patients presented
normal levels of blood and urinary calcemia and phospho-
remia. Normal level of osteocalcin (19.1 ± 8 ng/ml) (Fig. 4), but
hight level of bone alkaline phosphatase (24.2 ± 9.1 mg/L) (Fig.
5), and C- telopeptide (4528 ± 2821 pmol/L) (Fig. 6).
Discussion
In the general population osteoporosis is less common in men
than in women, with the incidence of vertebral fractures being
one sixth of that in women (3).
However, the sex difference was reversed in the thalassemia
patients studied here, with men being both more commonly
and more severely affected with low bone mass. This striking
observation is difficult to explain. Clinical experience indicates
that male thalassemia patients, particularly during their adoles-
cent years, are less compliant than females with DFX therapy.
The impact of this on peak bone mass, even with subsequent
improvement in chelation compliance as they improve chela-
tion therapy, may contribute to the sex difference in observed
bone mineral density. However, we could find no significant
correlation between severely low bone mass and serum ferritin
levels, measured at the time of this study. In a study of 17
transfusion-dependent children with thalassemia also no ap-
parent association between iron overload and vitamin D defi-
ciency and bone disease was found (4).
The most common endocrine disorder among our patients is
hypogonadotrophic hypogonadism. In the general population
hypogonadism is a well-recognized cause of overt osteoporo-
sis and of asymptomatic osteopenia. Oestrogen replacement
therapy for women is the most effective preventative measure
against postmenopausal osteoporosis. The exact mechanism
of action of oestrogen on bone, calcium and phosphorus me-
tabolism has not been determined, but oestrogens appear pri-
marily to inhibit osteoclastic activity and bone resorption (5).
It is important to note that therapeutic correction of hypogo-
nadism with appropriate HRT in these thalassemia patients has
failed to protect them from low bone mass.
In spite of regular blood transfusions the ineffective erythro-
poiesis is not fully suppressed in thalassemia major. Expansion
of the marrow may contribute to the decreased bone mineral
density. It is also possible that excess iron in the bone may in-
fluence osteoblast number and activity and lead to the develop-
ment of osteoporosis (6).
In the general population, osteoporosis is associated with a
sedentary lifestyle, but no association with current exercise
habits was apparent in this study. However, parental anxiety
may have limited participation in sporting activities during child-
hood and it is possible that this contributed to the development
of severely low bone mass.
As the longevity of patients with TM increases, osteoporosis
will become an increasingly prominent problem (7, 8). Osteo-
porosis is a progressive disease, so prevention and early diag-
nosis are important, as well as treatment of the established dis-
ease. The prevalence of clinical features of severely low bone
mass and results of its treatment in our patients will form the
basis of further investigations (9).
The average of bone density, that indicates an osteopenia,
doesn’t fully account for the real clinical state. The analysis of
individual values shows that the 50% of the TM patients is af-
fected with osteoporosis (defined as a reduction of the bone
mass > 2.5 DS), osteopenia in the 36% of the subjects, while
the 13% had a normal bone mass. 
Th re is a difference between men and women BMD, likely
due to the low compliance to the treatment in male subjects. In
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fact, the anamnestic study showed that almost none of the
male TM patients was on hormonal therapy. 
The BMD reduction is more marked at lumbar spine than femur.
It may be caused by the age: the reduction of the bone mass
starts at the beginning in the spine and just lately the femur.
Analysis of bone remodelling has shown, through the dosage
of bone markers that in thalassemic patients is very increased,
suggesting that both reabsorption and neoformation processes
are accelerated. 
Particularly, increased C telopeptides and alkaline phos-
phatase were observed, although osteocalcin is normal.
It’s possible that subjects with increased reabsorbtion, have a
marked bone loss and a progressive increased fracture risk. 
Bone remodelling is an evolutionary process, so that the BMD,
considering the high reabsorption markers, may be further re-
duced, with a consequential progressive increase of the frac-
ture risk. 
The mechanisms influencing negatively the risk fractures en-
clode the increase of the rate of bone loss, the impairment of
skeletal microarchitecture, trabeculae perforation and loss of
structural elements of the bone. 
It’s necessary to prevent a further loss of bone, in order to
avoid the risk of fractures. 
TM patients need to be treated because of the progressive os-
teoporosis. For this reason is not necessary just the HRT, but
specific antireabsorbitive drugs, able to improve bone turn over
and reduce the reabsorption. 
Likely, biphosphonates, blocking the bone reabsorption, are
the most indicated drugs for the treatment of osteoporosis in
TM patients.
N vertheless, we don’t know yet the long term efficacy and
safety of these drugs in TM patients, further studies are need-
e d 
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